Personalized neuroscience is a burgeoning field that integrates neuroscience with personalized medicine. It aims to understand individual differences in brain structure, function, and connectivity to tailor interventions and treatments for various neurological and psychiatric conditions. Traditional approaches in neuroscience often treat all individuals as similar, overlooking the inherent diversity in brain function and response to treatments. However, with advances in technology such as functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and genetics, researchers can now delve deeper into the unique characteristics of each person's brain. One of the key aspects of personalized neuroscience is the utilization of biomarkers to characterize brain health and predict responses to interventions. These biomarkers can include genetic markers, neural activity patterns, and neuroimaging signatures. By identifying these biomarkers, clinicians can develop personalized treatment plans that are tailored to an individual's specific neurobiological profile. Furthermore, personalized neuroscience holds promise in various domains, including mental health, neurodegenerative diseases, and cognitive enhancement. For example, in psychiatry, clinicians can use personalized neuroscience approaches to optimize medication selection and dosages based on a patient's neurobiological makeup, potentially minimizing side effects and improving treatment outcomes. In neurodegenerative diseases such as Alzheimer's and Parkinson's, personalized neuroscience may enable early detection and intervention, ultimately delaying disease progression. Overall, personalized neuroscience represents a paradigm shift in how we understand and treat neurological and psychiatric conditions. By recognizing and embracing individual variability in brain structure and function, researchers and clinicians can develop more effective and targeted interventions, ultimately improving patient outcomes and quality of life.
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Study of resilience in cases of incest, father-daughter, step-father and step-daughter in the pre-pubber and puberous period among adult women and mothers: How to overcome the traumatisms of an incestuous relationship?
Daniele Lapointe, Laval University, Canada
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom